Amedisys Inc Revenue Growth Rates (AMED), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Amedisys Inc  (NASDAQ: AMED)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare
 

AMED's Revenue Growth by Quarter and Year

Amedisys Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMED Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 621.86
1st Quarter March 594.78
FY 1,216.64

AMEDs Annual Revenue
Amedisys Inc's Revenue in the fiscal year 2024 $ 2,348.32 millions
Amedisys Inc's Revenue in the fiscal year 2023 $ 2,236.38 millions
Amedisys Inc's Revenue in the fiscal year 2022 $ 2,223.20 millions
Amedisys Inc's Revenue in the fiscal year 2021 $ 2,214.11 millions
Amedisys Inc's Revenue in the fiscal year 2020 $ 2,071.52 millions




AMED Revenue second quarter 2025 Y/Y Growth Comment
Amedisys Inc achieved in the second quarter 2025, above Company average Revenue improvement of 5.19% year on year, to $ 621.86 millions.

Looking into second quarter 2025 results within Healthcare Facilities industry 27 other companies have achieved higher Revenue growth. While Amedisys Inc' s Revenue increase of 5.19% ranks overall at the positon no. 2054 in the second quarter 2025.


AMED Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 4.78 % 1.55 % 0.49 %
3rd Quarter September - 5.65 % -0.31 % 0.81 %
2nd Quarter June 5.19 % 6.91 % -0.88 % -1.11 %
1st Quarter March 4.09 % 2.7 % 2.04 % 1.51 %
FY   - 5 % 0.59 % -

Financial Statements
Amedisys Inc's second quarter 2025 Revenue $ 621.86 millions AMED's Income Statement
Amedisys Inc's second quarter 2024 Revenue $ 591.19 millions Quarterly AMED's Income Statement


AMED Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 1.77 % 2.62 % 0.73 %
3rd Quarter September - -0.6 % 0.59 % 0.02 %
2nd Quarter June 4.55 % 3.46 % -0.61 % 2.32 %
1st Quarter March -0.55 % 0.11 % -1.01 % -2.51 %
FY (Year on Year)   - 5 % 0.59 % -


Back to AMED Growth rate Comparisons >> Back to AMED Growth rate Comparisons >>


Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #28
Healthcare Sector #357
Overall #2054

Revenue Y/Y Growth Statistics
High Average Low
19.77 % 2.02 % -100 %
(Dec 31 2019)   (March 31, 2014)
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #28
Healthcare Sector #357
Overall #2054
Revenue Y/Y Growth Statistics
High Average Low
19.77 % 2.02 % -100 %
(Dec 31 2019)   (March 31, 2014)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Amedisys Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
12.17 % -1.07 % -100 %
(Sep 30 2020)  


AMED's II. Quarter Q/Q Revenue Comment
Amedisys Inc achieved in the II. Quarter 2025 above company average sequential Revenue growth of 4.55%, to $ 621.86 millions, from $594.78 millions in the first quarter.
AMED is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Healthcare Facilities industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Amedisys Inc's Revenue growth quarter on quarter, overall rank is 2039.


Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #17
Healthcare Sector #356
Overall #2039
Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #17
Healthcare Sector #356
Overall #2039
Revenue Q/Q Growth Statistics
High Average Low
12.17 % -1.07 % -100 %
(Sep 30 2020)  


AMED's II. Quarter Q/Q Revenue Comment
Amedisys Inc achieved in the II. Quarter 2025 above company average sequential Revenue growth of 4.55%, to $ 621.86 millions, from $594.78 millions in the first quarter.
AMED is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Healthcare Facilities industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Amedisys Inc's Revenue growth quarter on quarter, overall rank is 2039.


Amedisys Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)
Cumulative Revenue 12 Months Ending $ 2,402.37 $ 2,371.69 $ 2,348.32 $ 2,321.06 $ 2,289.63
Y / Y Revenue Growth (TTM) 4.92 % 5.34 % 5.01 % 4.19 % 2.7 %
Year on Year Revenue Growth Overall Ranking # 2135 # 2098 # 2130 # 1650 # 604
Seqeuential Revenue Change (TTM) 1.29 % 1 % 1.17 % 1.37 % 1.7 %
Seq. Revenue Growth (TTM) Overall Ranking # 2264 # 2055 # 2160 # 1683 # 1603


Cumulative Revenue growth Comment
Assuming the Amedisys Inc's fiscal year would have ended in Jun 30 2025, Amedisys Inc would have reprted above average annual Revenue improvement of 4.92% year on year, of $ 2,402 millions.
This marks a slow-down of the companys growth trends and from the 5.34% growth in Mar 31 2025.

In the Healthcare sector 335 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2098 to 2135.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 28
Healthcare Sector # 336
Overall # 2135

Revenue TTM Y/Y Growth Statistics
High Average Low
17.62 %
 4.63 %
-16.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 346
S&P 500 # 2264
Cumulative Revenue growth Comment
Assuming the Amedisys Inc's fiscal year would have ended in Jun 30 2025, Amedisys Inc would have reprted above average annual Revenue improvement of 4.92% year on year, of $ 2,402 millions.
This marks a slow-down of the companys growth trends and from the 5.34% growth in Mar 31 2025.

In the Healthcare sector 335 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2098 to 2135.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 28
Healthcare Sector # 336
Overall # 2135

Revenue TTM Y/Y Growth Statistics
High Average Low
17.62 %
4.63 %
-16.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 346
S&P 500 # 2264




Other Revenue Growth
Healthcare Facilities Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AMED's Revenue Growth Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Waters Corporation8.86%$ 8.864 millions
Exagen Inc 8.84%$ 8.836 millions
Lftd Partners Inc 8.83%$ 8.833 millions
Steris Plc8.72%$ 8.722 millions
Plus Therapeutics Inc 8.68%$ 8.679 millions
Tandem Diabetes Care Inc 8.51%$ 8.514 millions
Embecta Corp 8.45%$ 8.453 millions
Surgery Partners Inc 8.41%$ 8.411 millions
Radnet Inc 8.38%$ 8.378 millions
Cadre Holdings inc 8.27%$ 8.274 millions
Adc Therapeutics Sa8.21%$ 8.208 millions
Curis Inc 7.97%$ 7.973 millions
Envista Holdings Corporation7.79%$ 7.793 millions
Tactile Systems Technology Inc 7.78%$ 7.784 millions
Amarin Corp Plcuk7.78%$ 7.779 millions
Royalty Pharma Plc7.71%$ 7.705 millions
National Vision Holdings Inc 7.68%$ 7.679 millions
Healthcare Services Group Inc 7.55%$ 7.554 millions
Orchestra Biomed Holdings Inc 7.46%$ 7.455 millions
Abbott Laboratories7.37%$ 7.372 millions
Biogen Inc 7.33%$ 7.327 millions
Fortrea Holdings Inc 7.23%$ 7.231 millions
Zimmer Biomet Holdings Inc 6.97%$ 6.967 millions
Infusystem Holdings Inc6.84%$ 6.837 millions
Abbvie Inc 6.65%$ 6.645 millions
Treace Medical Concepts Inc 6.60%$ 6.595 millions
Sotera Health Company6.47%$ 6.465 millions
Hca Healthcare Inc 6.36%$ 6.363 millions
Gyre Therapeutics Inc 6.13%$ 6.129 millions
Davita Inc 6.05%$ 6.050 millions


About Amedisys Inc Revenue Growth Rates (AMED), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Amedisys Inc (CIK 896262).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000896262-25-000065
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Amedisys Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.